Sectors
APGE
Apogee Therapeutics, Inc.
132.60
4 x 95.48
43 x 132.62
bid
ask
+
42.22
46.72%
02:12 PM
timesize
| Ytd | 75.68% | |
| 1y | 216.03% |
132.50
day range
133.00
34.65
52 week range
132.60
| Open | 132.55 | Prev Close | 90.38 | Low | 132.50 | High | 133.00 | Mkt Cap | 10.00B |
| Vol | 50.06M | Avg Vol | 974.52K | EPS | -4.33 | P/E | N/A | Forward P/E | -17.40 |
| Beta | 0.62 | Short Ratio | 12.80 | Inst. Own | 131.10% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-10 | 50-d Avg | 84.76 | 200-d Avg | 69.38 | 1yr Est | 119.50 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-05-11 | 2026-03 | 0 | N/A | N/A | N/A |
| 2026-03-02 | 2025-12 | 0 | N/A | N/A | N/A |
| 2025-11-10 | 2025-09 | 0 | N/A | 0.03 | 2.63% |
| 2025-11-10 | 2025-09 | 0 | N/A | N/A | N/A |
| 2025-08-11 | 2025-06 | 0 | N/A | -0.1 | -9.71% |
| 2025-08-11 | 2025-06 | 0 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-06-08 | RBC Capital | Upgrade | Sector Perform | Sector Perform |
| 2026-05-27 | Truist Securities | Upgrade | Hold | Hold |
| 2026-05-27 | BTIG | Upgrade | Buy | Buy |
| 2026-05-27 | Wedbush | Upgrade | Outperform | Outperform |
| 2026-05-01 | Rothschild & Co | Upgrade | Buy | |
| 2026-03-30 | Mizuho | Upgrade | Outperform | Outperform |
Profile
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of atopic dermatitis, which is in phase 2 clinical trials; and for the treatment of asthma and eosinophilic esophagitis which is in phase 1 clinical trial. It also develops APG279 which is in phase 1 clinical trial for the treatment of atopic dermatitis; APG273 which is in phase 1 clinical trial for the treatment of asthma and chronic obstructive pulmonary disease; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-06-02 | DAMBKOWSKI CARL | Officer | 205.65K | Sale |
| 2026-01-21 | FAIRMOUNT FUNDS MANAGEMENT LLC | Unknown | 0.00 | Sale |
| 2026-04-30 | HENDERSON JANE | Chief Financial Officer | 173.37K | Sale |
| 2026-06-09 | HENDERSON MICHAEL THOMAS | Chief Executive Officer | 1.10M | Sale |
| 2024-12-11 | MCKENNA MARK C | Director | 20.00K | Purchase |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | T. Rowe Price Investment Management, Inc. | 10.30M | 931.00M | 16.64% |
| 2026-03-30 | FMR, LLC | 9.26M | 837.13M | 14.96% |
| 2026-03-30 | Venrock Adviser, LLC | 8.49M | 767.63M | 13.72% |
| 2026-03-30 | Wellington Management Group, LLP | 4.38M | 395.48M | 7.07% |
| 2026-03-30 | Blackrock Inc. | 4.09M | 369.26M | 6.60% |
| 2026-03-30 | RTW Investments LP | 2.78M | 251.45M | 4.49% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | T. ROWE PRICE CAPITAL APPRECIATION Fd., INC.-T. Rowe Price Capital App | 5.30M | 478.65M | 8.56% |
| 2026-01-30 | VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 2.07M | 187.17M | 3.35% |
| 2026-03-30 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.84M | 166.33M | 2.97% |
| 2026-04-29 | Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 1.84M | 165.93M | 2.97% |
| 2026-04-29 | SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.27M | 114.62M | 2.05% |
| 2026-03-30 | JNL Series Trust-JNL/T. Rowe Price Capital Appreciation Fund | 1.13M | 101.74M | 1.82% |
